Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
Acute single-dose response of drug-induced parkinsonism (DIP) to L-Dopa and apomorphine challenge was evaluated in a double-blind crossover study in 12 schizophrenic patients. There were two noteworthy negative findings. First, neither L-Dopa nor apomorphine produced significant improvements in DIP and second, no changes (neither improvement nor worsening) were found in patients' psychiatric status. Findings suggest that, for a stimulation dose reaching almost 90% of the responsive dose for idiopathic Parkinson's disease, no significant changes may reasonably be expected in the parkinsonism of schizophrenic patients treated with neuroleptic drugs.
Department of Clinical Neurology, Neuropsychiatric Hospital, Raul Carrea Institute for Neurological Research FLENI, Buenos Aires, Argentina.
M
M
Merello
S
S
Starkstein
G
G
Petracca
E A
EA
Cataneo
F
F
Manes
R
R
Leiguarda
D000328:Adult; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D001058:Apomorphine / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D007980:Levodopa; D001058:Apomorphine